cAMPfield Therapeutics

About cAMPfield Therapeutics

cAMPfield Therapeutics is a clinical-stage biopharmaceutical company advancing oral therapies for inflammatory and immunological diseases. The company launched in June 2026 with a significant $180 million Series A financing round. This funding was supported by a syndicate of top-tier life sciences investors, including Novo Holdings, RA Capital Management, Frazier Life Sciences, and others. The company was established by Mountainfield Venture Partners, a firm that creates biopharmaceutical companies around promising development-stage drug candidates. cAMPfield's strategy focuses on in-licensing assets with the potential to transform patient care. The company is led by CEO Bill Gerhart, a seasoned executive with over two decades of experience in pulmonary, fibrotic, and inflammatory diseases and a track record of leading companies to successful mergers and acquisitions. Other key executives include Chief Technical Officer Patricia Turney and VP of Global Regulatory Affairs Rita Shah. cAMPfield's lead program is prifemilast, an oral phosphodiesterase-4 (PDE4) inhibitor being developed as a potential best-in-class treatment for Inflammatory Bowel Disease (IBD), which includes ulcerative colitis. The company aims to establish prifemilast as a preferred treatment option for IBD patients, offering robust disease control with a favorable safety profile. PDE4 inhibition is a clinically validated mechanism, and prifemilast has demonstrated efficacy in Phase 2 studies for ulcerative colitis. The global rights to the compound, also known as HPP737, were acquired from vTv Therapeutics and Newsoara Biopharma. The drug has undergone clinical testing for several indications, including psoriasis, COPD, and atopic dermatitis. Keywords: PDE4 inhibitor, prifemilast, inflammatory bowel disease, IBD, ulcerative colitis, immunology, oral therapeutics, biopharmaceutical, clinical-stage, Bill Gerhart, Mountainfield Venture Partners, Series A, Novo Holdings, RA Capital, Frazier Life Sciences, small molecule drugs, HPP737, psoriasis, COPD, atopic dermatitis